前沿速览016期| CAR-T治B淋 前沿览新知
01
FOXO1可增强CAR-T细胞的干细胞特性、代谢适应性和疗效
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
第一作者：Chan JD
Nature (IF=64.8). 2024 Apr 10.
全文网址：https://www.nature.com/articles/s41586-024-07242-1
02
大B细胞淋巴瘤二线治疗（Axicabtagene ciloleucel vs. 标准疗法）：按肿瘤代谢体积分层分析的结果
Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume
第一作者：Locke FL
Blood (IF=20.3). 2024 Apr 1:blood.2023021620.
全文网址：https://ashpublications.org/blood/article/doi/10.1182/blood.2023021620/515553/Axicabtagene-ciloleucel-versus-standard-of-care-in
03
CAR-T细胞疗法可使复发的原发性中枢神经系统淋巴瘤患者获得高长期缓解率：LOC网络的真实世界结果
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network
第一作者：Choquet S
Am J Hematol (IF=12.8). 2024 Apr 8.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/ajh.27316
04
用18F-FDG PET/CT 检测到1例难治性弥漫大B细胞淋巴瘤患者在接受CAR-T细胞治疗后出现脾脏假性进展
Splenic Pseudoprogression After CAR-T Therapy Detected by 18F-FDG PET/CT in a Refractory Diffuse Large B-Cell Lymphoma Patient
第一作者：Yao X
Clin Nucl Med (IF=10.6). 2024 Apr 8.
全文网址：https://journals.lww.com/nuclearmed/abstract/9900/splenic_pseudoprogression_after_car_t_therapy.1050.aspx
05
CAR-T细胞治疗大B细胞淋巴瘤亚型患者的结果
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
第一作者：Bourlon C
Haematologica (IF=10.1). 2024 Apr 4.
全文网址：https://haematologica.org/article/view/haematol.2024.285010
06
输注后PD-1+CD8+CAR-T细胞可识别对 CD19-CAR-T细胞疗法有应答的非霍奇金淋巴瘤患者
Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma
第一作者：Denlinger N
Blood Adv (IF=7.6). 2024 Mar 23:bloodadvances.2023012073.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023012073/515389/Post-infusion-PD-1-CD8-CAR-T-cells-identify
07
表达IL-15的CD70特异性CAR-NK细胞可用于治疗CD19阴性的B细胞恶性肿瘤
CD70-specific CAR-NK cells expressing IL-15 for the treatment of CD19-negative B cell malignancy
第一作者：Guo S
Blood Adv (IF=7.6). 2024 Apr 2:bloodadvances.2023012202.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023012202/515576/CD70-specific-CAR-NK-cells-expressing-IL-15-for
08
PD-1抑制剂维持治疗在接受CAR-T细胞治疗的复发/难治性B细胞非霍奇金淋巴瘤患者中的疗效
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
第一作者：Xin X
Cell Oncol (Dordr) (IF=6.6). 2024 Apr 2.
全文网址：https://link.springer.com/article/10.1007/s13402-024-00940-y
09
在英国接受CD19 CAR-T细胞治疗的大B细胞淋巴瘤患者中放疗桥接治疗的结果与可行性
Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK
第一作者：Kuhnl A
Br J Haematol (IF=6.5). 2024 Apr 9.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.19453
10
CAR-T细胞治疗淋巴瘤多学科团队综合病例管理中国专家共识
Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma
第一作者：Tu S
Chin Med J (Engl) (IF=6.1). 2024 Apr 3.
全文网址：https://journals.lww.com/cmj/fulltext/9900/chinese_expert_consensus_on_integrated_case.1025.aspx
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.4-16 valid until 2026.4
供稿与审核：临床开发与医学部